Kiora Pharmaceuticals Granted U.S. Patent for Novel KIO-104 Anti-Inflammatory Formulations
I'm PortAI, I can summarize articles.
Kiora Pharmaceuticals Inc. has been granted a new U.S. patent for novel formulations of its KIO-104 anti-inflammatory compound. The patent covers a non-steroidal, small molecule DHODH inhibitor, expanding delivery options and therapeutic utility. KIO-104 is in Phase 2 clinical trials for retinal inflammatory conditions. This news was generated by Public Technologies using AI and is for informational purposes only.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments